BioSpace News Archive

Along with temperatures dropping and COVID-19 cases resurging, this 2020 fall and winter also ushers in flu season, heightening the chances that a patient may be infected not only with strands of the flu or COVID-19, but could be experiencing a coinfection of both.

AbbVie GK and Eisai Co., Ltd. today announced an approval of additional indication of HUMIRA (generic name: adalimumab [recombinant], hereafter “HUMIRA”), a fully human anti-TNFalpha monoclonal antibody, for the treatment of pyoderma gangrenosum (hereafter “PG”).

Congratulations to Mike Melo, LifeLabs’ Chief Information Security Officer (CISO), for being awarded ‘CISO of the Year’ at the 2020 CISO Forum Canada. The award, presented by the world’s leading Cybersecurity and e-Business certification awarding body (and the creator of the world famous Certified Ethical Hacker certification) EC-Council and siberX, recognizes one individual who has truly navigated through the new normal with an innovative and strong

Using wastewater-based epidemiology techniques, SARS-CoV-2 is detectable up to a week before the traditional onset of COVID-19 symptoms within a population, giving communities more time to react.

X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, announced that, on November 30, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced positive results for the Phase 2 long-term safety study evaluating ARQ-151 (topical roflumilast cream) 0.3% as a potential once-daily chronic topical treatment for plaque psoriasis.

Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced it has submitted to the U.S. Food and Drug Administration (FDA) a protocol to initiate a clinical study in adult patients with neurotrophic keratitis (NK), a degenerative disease characterized by decreased corneal sensitivity and poor corneal healing.

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced that it intends to offer and sell in an underwritten public offering up to $250 million of shares of its common stock and certain selling stockholders intend to offer 75,000 shares in the offering.

Scientific Industries, Inc. announced its entry into an agreement to sell substantially all the assets of the Company’s subsidiary, Altamira Instruments, Inc. which has operated and housed the Company’s catalyst research instruments operations in Pittsburgh, PA since its acquisition in November, 2006, to Beijing JWGB Sci. & Tech. Co., Ltd for aggregate consideration of $440,000 in cash and promissory notes.

Brings 25 years of Financial Leadership, Significant Public Company Experience, and M&A Expertise to Company